Mylan, Disney expand allergy-fighting partnership with new website

Carly Helfand Parents whose children have potentially life-threatening allergies now have some new resources–thanks to Mylan and Disney, which have teamed up to launch MyAllergyKingdom.com.  FiercePharma ...

UPDATED: Heard the latest Kite Pharma rumor? CEO says it ain’t so

John Carroll Kite CEO Arie Belldegrun has a simple message for investors this morning: Relax. FierceBiotech News

Novo says new U.S. plant may be best bet to offset the FX bite

Eric Palmer Novo Nordisk has forecast that currency hedging losses will leave it with an $ 850 million net loss for the year. But CEO Lars Rebien Sørensen thinks he may have ...

Art Krieg leads Checkmate as it comes out of stealth mode with $20M

Alok Saboo FierceBiotech News

Takeda Actos settlement seems shaky as plaintiffs give it the sniff test

Eric Palmer Takeda's new CEO, Christophe Weber, thought the Japanese drugmaker had freed itself of the drag from thousands of lawsuits tied to cancer risks from its diabetes drug ...

With more consolidation on tap in generics, who’s next to buy and be bought?

Carly Helfand FiercePharma News

Baxalta responds to a frustrated Shire: The answer is still ‘no’

John Carroll Baxalta execs didn't like the idea of a $ 30 billion all-share Shire buyout when they heard it the first time on July 10–and they didn't warm to it at all ...

Apogenix inks cancer drug development deal for China

John Carroll Germany's Apogenix, which is backed by SAP co-founder Dietmar Hopp, has struck an exclusive licensing agreement with CANbridge Life Sciences to develop and commercialize ...

Biotech legend Lee Hood gambles $36M on a plan to revolutionize healthcare

John Carroll FierceBiotech News

House passes 21st Century Cures bill

Eric Palmer Members of U.S. House of Representatives voted 344 to 77 today to approve the 21st Century Cures bill. It now goes to the Senate for consideration. The bill provides more ...

Alexion gets EU green light for a pair of rare disease drugs

Damian Garde European regulators are recommending approval for two rare disease treatments from Alexion, a victory for the biotech as it works to expand its stable of commercialized ...

Biotie ups IPO as UCB exits, Targovax merges to forge Nordic I-O player, Cosmo plans IPO

Nick Paul Taylor In this week's EuroBiotech Report, Biotie Therapies, Cosmo Pharmaceuticals, Targovax and Pieris Pharmaceuticals are all advancing plans to raise cash from public ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS